“Vaccine for COVID-19 not an easy route, parallel drug discovery efforts required too”

At a recent media briefing, Dr Vinod Paul, Member NITI Aayog and Professor K. Vijay Raghavan, Principal Scientific Adviser to the Government of India, summarised activities on COVID-19 related to Science and Technology in the areas of vaccines, drug discovery, diagnostics and testing

0
28
The Principal Scientific Adviser to the Government of India, Prof. K. Vijay Raghavan addressing a press conference on the development of drugs, vaccines and technologies for testing during COVID-19 Pandemic, in New Delhi on May 28, 2020.

New Delhi: At a recent media briefing, Dr Vinod Paul, Member NITI Aayog and Professor K. Vijay Raghavan, Principal Scientific Adviser to the Government of India, summarised activities on COVID-19 related to Science and Technology in the areas of vaccines, drug discovery, diagnostics and testing.

On vaccines, it was pointed out that the process is usually slow and fraught with uncertainties. But, in order to succeed against COVID-19 a large number of parallel efforts are needed. This is being done globally and nationally. Indian academia and start-ups are working on vaccine candidates in the very strong Indian vaccine industry. There are three kinds of attempts being made. The first are indigenous efforts. The second are globally collaborative efforts where Indian organizations are taking a lead role and the third is Indian participation in global efforts. With such a large portfolio, followed by efforts at risk- mitigation for manufacturing and stockpiling, success is better assured.

“On drug discovery, our scientific efforts take three approaches. The first is the repurposing of extant drugs to see how effective they are against the virus and in mitigating the consequences of the disease. Second, Phyto-pharmaceuticals and extracts from medicinal plants are being tested. Finally, using a variety of approaches, new drug discovery including a ‘Hackathon’ for computational drug discovery is being undertaken,” mentioned Prof Vijayraghavan.

Speakers also pointed towards the conglomeration of research efforts that have resulted in new tests and testing kits. These include new tests for detection of the virus and also for antibody detection. The latter are being used for serological studies, “The speed of these developments is made possible by the collaborative efforts of our scientists, institutions and science agencies. The regulatory system has also been closely engaged, combining speed with quality.”